ubenimex Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor. It is an inhibitor of arginyl aminopeptidase (aminopeptidase B), leukotriene A4 hydrolase (a zinc metalloprotease that displays both epoxide hydrolase and aminopeptidase activities), alanyl aminopeptidase (aminopeptidase M/N), leucyl/cystinyl aminopeptidase (oxytocinase/vasopressinase), and membrane dipeptidase (leukotriene D4 hydrolase). It is being studied for use in the treatment of acute myelocytic leukemia and lymphedema. It is derived from Streptomyces olivoreticuli. Ubenimex has been found to inhibit the enzymatic degradation of oxytocin, vasopressin, enkephalins, and various other peptides and compounds.   Wikipedia

Chemistry

  • SMILES: CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O
  • InChIKey: VGGGPCQERPFHOB-RDBSUJKOSA-N
  • Mol. Mass: 308.38
  • ALogP: 0.53
  • ChEMBL Molecule:
    ubenimex  
More Chemistry

Pharmacology

Alternative names

(3-amino-2-hydroxy-4-phenylbutanoyl)-l-leucine | 3-amino-2-hydroxy-4-phenylbutyryl-l-leucine | bestatin | bestatin, (d-leu)-(r-(r*,r*))-isomer | bestatin, (d-leu)-(r-(r*,s*))-isomer | bestatin, (d-leu)-(s-(r*,s*))-isomer | bestatin, (l-leu)-(r-(r*,r*))-isomer | bestatin, (l-leu)-(r-(r*,s*))-isomer | bestatin, (l-leu)-(s-(r*,r*))-isomer | bestatin, (l-leu)-(s-(r*,s*))-isomer, hydrochloride | ubenimex

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Lymphedema (Phase 2)

Pulmonary Arterial Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue